Metraipolis › archive › dc_d2eb93a8a605

SUITOR: Selecting the number of mutational signatures through cross-validation — Europe PMC PMID:35377867

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/35377867
DOI: 10.1371/journal.pcbi.1009309
License (as archived): CC0-1.0
Archived: 2026-10-19T08:44:53.792Z
SHA-256 of the archived text: 35ff251171963b26afd612ed1c1d113f9259e37ceb560553266b6847f53fdc55
Stable URL of this page: https://metraipolis.com/documento/dc_d2eb93a8a605

How to cite

SUITOR: Selecting the number of mutational signatures through cross-validation — Europe PMC PMID:35377867 — Europe PMC (en), https://europepmc.org/article/MED/35377867 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_d2eb93a8a605 (Metraipolis archive dc_d2eb93a8a605, sha256 35ff251171963b26afd612ed1c1d113f9259e37ceb560553266b6847f53fdc55)

BibTeX

@misc{dcd2eb93a8a605,
  title = {SUITOR: Selecting the number of mutational signatures through cross-validation — Europe PMC PMID:35377867},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/35377867},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_d2eb93a8a605; sha256 35ff251171963b26afd612ed1c1d113f9259e37ceb560553266b6847f53fdc55},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/35377867. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

For de novo mutational signature analysis, the critical first step is to decide how many signatures should be expected in a cancer genomics study. An incorrect number could mislead downstream analyses. Here we present SUITOR (Selecting the nUmber of mutatIonal signaTures thrOugh cRoss-validation), an unsupervised cross-validation method that requires little assumptions and no numerical approximations to select the optimal number of signatures without overfitting the data. In vitro studies and in silico simulations demonstrated that SUITOR can correctly identify signatures, some of which were missed by other widely used methods. Applied to 2,540 whole-genome sequenced tumors across 22 cancer types, SUITOR selected signatures with the smallest prediction errors and almost all signatures of breast cancer selected by SUITOR were validated in an independent breast cancer study. SUITOR is a powerful tool to select the optimal number of mutational signatures, facilitating downstream analyses with etiological or therapeutic importance.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS computational biology, 2022 (prima pubblicazione 2022-04-04).
Identificativi: PMID 35377867 · PMCID PMC9009674 · DOI 10.1371/journal.pcbi.1009309.
Descrittori MeSH principali: Neoplasms; Breast Neoplasms.
Pagina: https://europepmc.org/article/MED/35377867 — https://doi.org/10.1371/journal.pcbi.1009309. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-10-19T08:41:04.791Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.